Carpal Tunnel Syndrome Market Size to Worth USD 1,328.69 Mn by 2032 [Yahoo! Finance]
PAVmed Inc. (PAVM)
US:NASDAQ Investor Relations:
ir.pavm.com
Company Research
Source: Yahoo! Finance
Ottawa, May 24, 2024 (GLOBE NEWSWIRE) -- The global carpal tunnel syndrome market size was valued at USD 942.69 million in 2023 and is predicted to hit around USD 1,232.21 million by 2031, a study published by Towards Healthcare a sister firm of Precedence Research. Download the sample report to explore the projected growth of the carpal tunnel syndrome market from 2024 to 2032 @ Get Carpal Tunnel Syndrome Market Sample Report Here Report Highlights: Integrative therapy reported a significant 38% market share in 2023. NSAIDs were the most popularly used medications in 2023. North America accounted for the dominant 32% market share in 2023. Doing certain types of work can lead to more cases of Carpal Tunnel Syndrome. The US Department of Labor and Statistics found that for every 10,000 workers, about 0.5 of them develop Carpal Tunnel Syndrome because of their jobs. 90% of all cases of neuropathy are caused by carpal tunnel syndrome, the most common focal mononeuropathy.
Show less
Read more
Impact Snapshot
Event Time:
PAVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PAVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PAVM alerts
High impacting PAVmed Inc. news events
Weekly update
A roundup of the hottest topics
PAVM
News
- PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstitutePR Newswire
- PAVmed Inc. (NASDAQ: PAVM) was upgraded by analysts at Lake Street Capital to a "strong-buy" rating.MarketBeat
- PAVmed Non-GAAP EPS of -$0.99 beats by $0.56, revenue of $1.01M misses by $0.03M [Seeking Alpha]Seeking Alpha
- PAVmed Provides Business Update and First Quarter 2024 Financial ResultsPR Newswire
- PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024PR Newswire
PAVM
Analyst Actions
- 5/17/24 - Lake Street Capital
PAVM
Sec Filings
- 6/20/24 - Form 8-K
- 5/14/24 - Form 8-K
- 5/13/24 - Form 10-Q
- PAVM's page on the SEC website